Trial Profile
A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects With Schizophrenia and Subjects With Irritability Associated With Autistic Disorder
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Lurasidone (Primary)
- Indications Autistic disorder; Bipolar depression; Bipolar I disorders; Schizophrenia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 03 May 2021 According to Sunovion Pharmaceuticals media release, results from this trial presented at The American Psychiatric Association (APA) Annual Meeting
- 15 Sep 2020 Results of post-hoc analysis evaluating the long-term efficacy of lurasidone in achieving response or remission in children and adolescents with bipolar depression presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology
- 15 Sep 2020 Results of post hoc analysis evaluating the proportion of adolescent patients with schizophrenia who achieved sustained remission and recovery during 2 years of treatment with lurasidone presented at the 33rd Annual Congress of the European College of Neuropsychopharmacology